Publications by authors named "S I Al-Akash"
Article Synopsis
- * An 11-year-old boy exhibited severe symptoms including flank pain and foamy urine, with genetic testing revealing a novel pathogenic variant associated with the disease.
- * The case highlights the importance of genetic testing for early diagnosis in patients with renal issues, especially when there is a family history of kidney disease.
Article Synopsis
- IgA vasculitis (IgAV) is a pediatric disease characterized by skin and systemic symptoms, and researchers conducted comprehensive studies involving genome, transcriptome, and proteome analyses on a large cohort of IgAV patients and controls to better understand the disease mechanisms.* -
- Significant associations were found with specific genetic risk factors, including two novel non-HLA loci linked to IgA receptor functioning, which may contribute to disease development through altered immune responses.* -
- Systems biology approaches helped identify key regulatory networks and master regulators in myeloid cells, along with 21 genetic loci that overlap with IgA nephropathy, suggesting shared pathways in these related conditions.*
Article Synopsis
- Probiotics are beneficial microorganisms that may improve health, but their use in pediatric kidney transplant recipients is not well studied.
- A survey of pediatric nephrologists revealed that about 42.2% have prescribed probiotics to these patients primarily for treating antibiotic-associated diarrhea, with concerns about safety impacting their use.
- There is considerable variation in practice among nephrologists regarding probiotic use, emphasizing the need for more research on safety and effectiveness in transplant recipients.
Background: There are scant data on the effect of rituximab on EBV DNA levels and prevention of post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplant recipients with EBV DNAemia.
Methods: Kidney transplant recipients with EBV DNAemia treated with rituximab to prevent PTLD between 7/1999 and 7/2019 at five pediatric centers were included. Those with confirmed PTLD at the onset of rituximab were excluded.
Background: We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC).
Methods: Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test.
Results: From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients.